106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2017 All rights reserved
Disclaimer
is pocket card is derived om recommendations in the American Society of Clinical Oncolog y
Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is not intended to
substitute for the independent professional judgment of the treating physician. Practice guidelines do
not account for individual variation among patients. is pocket card does not purport to suggest any
particular course of medical treatment. Use of the practice guidelines and this resource are voluntary.
e practice guidelines and additional information are available at www.asco.org/breast-cancer-
guideline. Copyright © 2017 by American Society of Clinical Oncolog y. All rights reserved.
ASCOBIOearly17072b
Abbreviations
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IHC,
immunohistochemistry; PR, progesterone receptor; PTEN, phosphatase and tensin homolog ;
RS, recurrence score; TN, triple negative
Source
Krop I et al. Use Of Biomarkers To Guide Decisions On Adjuvant Systemic erapy For Women
With Early-Stage Invasive Breast Cancer: Focused Update Of 2016 American Society Of
Clinical Oncolog y Clinical Practice Guideline
Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond
EH, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Bast RC, Hayes DF; American Society
of Clinical Oncolog y. Use of Biomarkers to Guide Decisions on Adjuvant Systemic erapy
for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncolog y
Clinical Practice Guideline. J Clin Oncol. 2016 Apr 1;34(10):1134-50.
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, patient
versions, frequently asked questions, and other clinical tools and resources, is available at
www.asco.org/breast-cancer-guidelines and www.asco.org/guidelineswiki
Recommendation Grading
Type Evidence Quality
Strength of
Recommendation
EB Evidence-based H High Strong
IC Informal consensus I Intermediate Moderate
L Low Weak
Ins Insufficient
